

Jie Wang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5077630/publications.pdf>

Version: 2024-02-01

42
papers

4,399
citations

623188

14
h-index

360668

35
g-index

44
all docs

44
docs citations

44
times ranked

5333
citing authors

#	ARTICLE	IF	CITATIONS
1	Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. <i>Lancet, The</i> , 2019, 393, 1819-1830.	6.3	2,347
2	Assessment of Blood Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Patients With Nonâ€“Small Cell Lung Cancer With Use of a Next-Generation Sequencing Cancer Gene Panel. <i>JAMA Oncology</i> , 2019, 5, 696.	3.4	380
3	Epidermal Growth Factor Receptor Mutations in Plasma DNA Samples Predict Tumor Response in Chinese Patients With Stages IIIB to IV Nonâ€“Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 2653-2659.	0.8	281
4	Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical Trial. <i>Journal of Thoracic Oncology</i> , 2019, 14, 867-875.	0.5	260
5	Influence of Chemotherapy on <i>EGFR</i> Mutation Status Among Patients With Nonâ€“Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2012, 30, 3077-3083.	0.8	188
6	Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Nonâ€“Small-Cell Lung Cancer. <i>JAMA Oncology</i> , 2021, 7, 709.	3.4	185
7	TCR Repertoire Diversity of Peripheral PD-1+CD8+ T Cells Predicts Clinical Outcomes after Immunotherapy in Patients with Nonâ€“Small Cell Lung Cancer. <i>Cancer Immunology Research</i> , 2020, 8, 146-154.	1.6	166
8	Tislelizumab in Chinese patients with advanced solid tumors: an open-label, non-comparative, phase 1/2 study. , 2020, 8, e000437.		86
9	Anlotinib vs placebo as third- or further-line treatment for patients with small cell lung cancer: a randomised, double-blind, placebo-controlled Phase 2 study. <i>British Journal of Cancer</i> , 2021, 125, 366-371.	2.9	71
10	Allele Frequencyâ€“Adjusted Blood-Based Tumor Mutational Burden as a Predictor of Overall Survival for Patients With NSCLC Treated With PD-(L)1 Inhibitors. <i>Journal of Thoracic Oncology</i> , 2020, 15, 556-567.	0.5	66
11	Metagenome association study of the gut microbiome revealed biomarkers linked to chemotherapy outcomes in locally advanced and advanced lung cancer. <i>Thoracic Cancer</i> , 2021, 12, 66-78.	0.8	32
12	A Phase 2 Study of Tislelizumab in Combination With Platinum-Based Chemotherapy as First-line Treatment for Advanced Lung Cancer in Chinese Patients. <i>Lung Cancer</i> , 2020, 147, 259-268.	0.9	31
13	Upfront dose-reduced chemotherapy synergizes with immunotherapy to optimize chemoimmunotherapy in squamous cell lung carcinoma. , 2020, 8, e000807.		29
14	Epigenetic alterations are associated with tumor mutation burden in non-small cell lung cancer. , 2019, 7, 198.		28
15	EPHA mutation as a predictor of immunotherapeutic efficacy in lung adenocarcinoma. , 2020, 8, e001315.		24
16	Recommendations of individualized medical treatment and common adverse events management for lung cancer patients during the outbreak of COVID â€“19 epidemic. <i>Thoracic Cancer</i> , 2020, 11, 1752-1757.	0.8	20
17	Refined Stratification Based on Baseline Concomitant Mutations and Longitudinal Circulating Tumor DNA Monitoring in Advanced EGFR-Mutant Lung Adenocarcinoma Under Gefitinib Treatment. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1857-1870.	0.5	19
18	Association between recent oncologic treatment and mortality among patients with carcinoma who are hospitalized with COVIDâ€“19: A multicenter study. <i>Cancer</i> , 2021, 127, 437-448.	2.0	17

#	ARTICLE	IF	CITATIONS
19	Clinical outcomes and radiation pneumonitis after concurrent EGFR tyrosine kinase inhibitors and radiotherapy for unresectable stage III non-small cell lung cancer. Thoracic Cancer, 2021, 12, 814-823.	0.8	17
20	Transbronchoscopic patient biopsy-derived xenografts as a preclinical model to explore chemorefractory-associated pathways and biomarkers for small-cell lung cancer. Cancer Letters, 2019, 440-441, 180-188.	3.2	15
21	A novel tumor mutational burden estimation model as a predictive and prognostic biomarker in NSCLC patients. BMC Medicine, 2020, 18, 232.	2.3	15
22	Influence of adjuvant chemotherapy on survival for patients with stage IB and IIA non-small cell lung cancer. Thoracic Cancer, 2021, 12, 30-39.	0.8	13
23	Weighting tumor-specific TCR repertoires as a classifier to stratify the immunotherapy delivery in non-small cell lung cancers. Science Advances, 2021, 7, .	4.7	12
24	Apatinib, a novel VEGFR inhibitor plus docetaxel in advanced lung adenocarcinoma patients with wild-type EGFR: a phase I trial. Investigational New Drugs, 2019, 37, 731-737.	1.2	11
25	Identification and validation of tissue or ctDNA PTPRD phosphatase domain deleterious mutations as prognostic and predictive biomarkers for immune checkpoint inhibitors in non-squamous NSCLC. BMC Medicine, 2021, 19, 239.	2.3	11
26	Rare case of a patinib acquired resistance induced by point mutation of WRN p.V697F through activation of the PI3K/AKT apoptosis-inhibiting pathway. Thoracic Cancer, 2021, 12, 128-132.	0.8	8
27	Efficacy and safety of treatment modalities across EGFR selected/unselected populations with non-small cell lung cancer and brain metastases: A systematic review and Bayesian network meta-analysis. Lung Cancer, 2021, 158, 74-84.	0.9	8
28	Anlotinib for patients with small cell lung cancer and baseline liver metastases: A post hoc analysis of the ALTER 1202 trial. Cancer Medicine, 2022, 11, 1081-1087.	1.3	8
29	Alterations in EGFR and Related Genes following Neo-Adjuvant Chemotherapy in Chinese Patients with Non-Small Cell Lung Cancer. PLoS ONE, 2013, 8, e51021.	1.1	7
30	Efficacy and safety of immune checkpoint inhibitor consolidation after chemoradiation in patients of Asian ethnicity with unresectable stage III non-small cell lung cancer: Chinese multicenter report and literature review. Thoracic Cancer, 2020, 11, 2916-2923.	0.8	7
31	Individualized model for predicting COVID-19 deterioration in patients with cancer: A multicenter retrospective study. Cancer Science, 2021, 112, 2522-2532.	1.7	6
32	Peptidic microarchitecture-trapped tumor vaccine combined with immune checkpoint inhibitor or PI3K inhibitor can enhance immunogenicity and eradicate tumors. , 2022, 10, e003564.		6
33	Effectiveness of anlotinib in patients with small cell lung cancer and pleural effusion: Subgroup analysis from a randomized, multicenter, phase II study. Thoracic Cancer, 2021, 12, 3039-3045.	0.8	5
34	Reporting quality of randomized, controlled trials evaluating immunotherapy in lung cancer. Thoracic Cancer, 2021, 12, 2732-2739.	0.8	4
35	Development and validation of a prediction model using molecular marker for long-term survival in unresectable stage III non-small cell lung cancer treated with chemoradiotherapy. Thoracic Cancer, 2022, 13, 296-307.	0.8	4
36	Brigatinib treated ALK positive lung squamous cell carcinoma after failed chemotherapy: A case report. Thoracic Cancer, 2021, 12, 3273-3276.	0.8	3

#	ARTICLE	IF	CITATIONS
37	Evolution and genotypic characteristics of small cell lung cancer transformation in non-small cell lung carcinomas. <i>Journal of the National Cancer Center</i> , 2021, 1, 153-162.	3.0	3
38	Lung cancer and intraocular metastasis in gestation: Clinical experiences of a rare case. <i>Thoracic Cancer</i> , 2020, 11, 2723-2726.	0.8	2
39	Optimal Initial Time Point of Local Radiotherapy for Unresectable Lung Adenocarcinoma: A Retrospective Analysis on Overall Arrangement of Local Radiotherapy in Advanced Lung Adenocarcinoma. <i>Frontiers in Oncology</i> , 2022, 12, 793190.	1.3	2
40	Establishment of prognostic nomograms for predicting the progression free survival of EGFR sensitizing mutation, advanced lung cancer patients treated with EGFR TKIs. <i>Thoracic Cancer</i> , 2022, 13, 1289-1298.	0.8	1
41	Predictive Value of Max's Giant Associated Protein Mutation in Outcomes of Lung Adenocarcinoma Patients Treated With Immune Checkpoint Inhibitors. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 728647.	1.8	0
42	Biomarker subset analysis of a phase IIIb, open-label study of afatinib in EGFR tyrosine kinase inhibitor-naïve patients with EGFR ^{m+} non-small-cell lung cancer. <i>Future Oncology</i> , 2022, 18, 1485-1497.	1.1	0